Envestnet Asset Management
AVIR icon

Envestnet Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Envestnet Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,173
Closed -$97K – 3974
2022
Q4 		$97K Buy
20,173
+2,494
+14% +$12.6K ﹤0.01% 3818
2022
Q3 		$101K Buy
17,679
+572
+3% +$4.38K ﹤0.01% 3735
2022
Q2 		$121K Buy
17,107
+2,410
+16% +$16.5K ﹤0.01% 3736
2022
Q1 		$106K Buy
+14,697
New +$99.8K ﹤0.01% 3796

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Envestnet Asset Management's AVIR Position: Q1 2023 in Review

Envestnet Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 20,173 shares — an estimated $97K sold.

Envestnet Asset Management first reported a position in AVIR in Q1 2022 and held it in 4 quarters. The position peaked at $121K in Q2 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Envestnet Asset Management reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 20,173 Atea Pharmaceuticals shares in Q1 2023, an estimated $97K.
  • Envestnet Asset Management first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Envestnet Asset Management's Atea Pharmaceuticals position peaked at $121K in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.